SMMT Quote, Financials, Valuation and Earnings

Insmed, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of -259.95%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Insmed, Inc.'s return on equity of -193.23%.

Summit Therapeutics, Inc. has a consensus price target of $32.94, signalling upside risk potential of 119.77%. On the other hand Insmed, Inc. has an analysts' consensus of $215.15 which suggests that it could grow by 43.57%. Given that Summit Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Insmed, Inc..

Summit Therapeutics, Inc. has a beta of -1.438, which suggesting that the stock is 243.752% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Summit Therapeutics, Inc.'s net income of -$231.8M is higher than Insmed, Inc.'s net income of -$370M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 63.77x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 34.4%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Eli Lilly & Co.'s return on equity of 106.26%.

Summit Therapeutics, Inc. has a consensus price target of $32.94, signalling upside risk potential of 119.77%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,186.19 which suggests that it could grow by 11.82%. Given that Summit Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Summit Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Summit Therapeutics, Inc. has a beta of -1.438, which suggesting that the stock is 243.752% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.57% to investors and pays a quarterly dividend of $1.50 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 14.60x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of -39.75%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Summit Therapeutics, Inc. has a consensus price target of $32.94, signalling upside risk potential of 119.77%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $664.47 which suggests that it could grow by 38.29%. Given that Summit Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Summit Therapeutics, Inc. has a beta of -1.438, which suggesting that the stock is 243.752% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.010, suggesting its less volatile than the S&P 500 by 201.017%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 14.30x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Soleno Therapeutics, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 39.4%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Soleno Therapeutics, Inc.'s return on equity of -26.56%.

Summit Therapeutics, Inc. has a consensus price target of $32.94, signalling upside risk potential of 119.77%. On the other hand Soleno Therapeutics, Inc. has an analysts' consensus of $111.92 which suggests that it could grow by 169.5%. Given that Soleno Therapeutics, Inc. has higher upside potential than Summit Therapeutics, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than Summit Therapeutics, Inc..

Summit Therapeutics, Inc. has a beta of -1.438, which suggesting that the stock is 243.752% less volatile than S&P 500. In comparison Soleno Therapeutics, Inc. has a beta of -3.156, suggesting its less volatile than the S&P 500 by 415.592%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Soleno Therapeutics, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Soleno Therapeutics, Inc. quarterly revenues of $66M. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Soleno Therapeutics, Inc.'s net income of $26M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Soleno Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 20.57x for Soleno Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.